Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240

Summary

The goal of this study is to execute a small clinical proof of concept trial: To examine the effects of losartan on mucociliary clearance (MCC) in patients not eligible for CFTR rescue therapies

Timeline

Start

2022-02-15

Primary completion

2025-09-03

Completion

2026-03-31

Publications

• Bengtson CD, Schmid A, Kim MD, Dennis JS, Leeder JS, Zeman KL, Bennett WD, Sabater J, Baumlin N, Salathe M. Oral losartan yields subtherapeutic airway exposure compared to nebulized delivery and fails to improve mucociliary clearance in cystic fibrosis. Front Pharmacol. 2026 May 4;17:1807581. doi: 10.3389/fphar.2026.1807581. eCollection 2026.

Drugs

Indications